Skip to content
TrialMatch
Sign up
Recruiting

A Multicenter Cancer Biospecimen Collection Study

Create a profile to match View the full record on ClinicalTrials.gov

About this study

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

Condition
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer
Tested
OncoPrism™ assay
Sponsor
Cofactor Genomics, Inc.

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 21

  • Minimum age: 18 years
  • Study condition: Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer
  • Subject must have a disease of interest. Specifically, subject must have one of:
  • head and neck squamous cell carcinoma (HNSCC)
  • non-small-cell lung cancer (NSCLC)
  • small cell lung cancer (SCLC)
  • urothelial carcinoma (UCC)
  • gastric or gastroesophageal junction adenocarcinoma
  • cervical cancer
  • esophageal squamous cell carcinoma (ESCC)
  • triple-negative breast cancer (TNBC)
  • hepatocellular carcinoma (HCC)
  • renal cell carcinoma (RCC)
  • colorectal cancer (CRC)
  • Subject must have received, or be scheduled to receive, at least one dose of anti-PD-1/PD-L1 immunotherapy for treatment of their cancer.
  • Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1/PD-L1 immunotherapy.
  • Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1/PD-L1 immunotherapy.
  • Willing to provide electronic informed consent per IRB-approved protocol.
  • Able to speak, read, and comprehend English fluently.
  • Subject is 18 years of age or older.
  • Subjects must have sufficient tissue available to fulfill the specimen requirements of the study.

Exclusion 3

  • Inability or unwillingness to provide informed consent.
  • Subject who does/did not have one of the cancers listed above (other histologies).
  • Subject has already participated in this trial.

Where

1 site, 1 recruiting

Curebase

San Francisco, California, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.